Metraipolis › archive › dc_e86b568dcd6e

CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy — Europe PMC PMID:41347070

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41347070
DOI
10.3389/fonc.2025.1670033
License (as archived)
solo-consultazione
Archived
2026-11-08T10:58:02.328Z
SHA-256 of the archived text
70f741751cee1aa199b6585618dc6a506db0e103fc0ef449435ec993fe9421d9
Stable URL of this page
https://metraipolis.com/documento/dc_e86b568dcd6e

How to cite

CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy — Europe PMC PMID:41347070 — Europe PMC (en), https://europepmc.org/article/MED/41347070 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e86b568dcd6e (Metraipolis archive dc_e86b568dcd6e, sha256 70f741751cee1aa199b6585618dc6a506db0e103fc0ef449435ec993fe9421d9)
BibTeX
@misc{dce86b568dcd6e,
  title = {CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy — Europe PMC PMID:41347070},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41347070},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e86b568dcd6e; sha256 70f741751cee1aa199b6585618dc6a506db0e103fc0ef449435ec993fe9421d9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41347070. Agents can read the archived copy with the MCP tool read_document.